Entero Healthcare Q1 FY27 Earnings Call Transcript Released
Entero Healthcare Solutions reported Q1 FY27 consolidated revenue growth of 38.2% to ₹1,940 crores, with EBITDA margin at 5%. PAT increased by 72% to ₹52 crores. ROCE and ROE improved significantly to 21.1% and 20.4% respectively. The company reaffirmed its FY27 revenue growth guidance of 23% and EBITDA margin of 5%.
The announcement provides detailed financial results, margin improvements, and strategic outlook, which are highly material for investors and stakeholders in assessing the company's performance and future prospects.
The company reported strong year-on-year growth in revenue and profit, improved margins, and enhanced return ratios, exceeding initial expectations for the quarter and reaffirming positive future guidance.
Entero Healthcare Solutions Limited has released the transcript of its Q1 FY27 earnings conference call, which was held on August 10, 2026. The call discussed the company's unaudited financial results for the quarter ended June 30, 2026.
During the call, management highlighted a strong start to FY27 with consolidated revenue growing 38.2% year-on-year to ₹1,940 crores. On a like-for-like basis, adjusting for revenue recognition and divestments, the growth was even stronger at 40% year-on-year. EBITDA margin reached 5% for the quarter, meeting the full-year guidance in Q1 itself. Organic revenue growth was reported at 17.8% (19.6% like-for-like), exceeding the pharmaceutical market growth of 13.8%. Inorganic growth stood at 20.4%, solely from acquisitions made in the previous year, with no new acquisitions in Q1 FY27. The company's priority for the year is consolidation and integration, with a focus on organic growth.
Gross margin expanded by 147 basis points to 11.4%, and EBITDA margin improved by 143 basis points to 5%, with EBITDA growing 94% year-on-year. These improvements were driven by economies of scale in procurement, an increasing share of MedTech business, and the exit from low-margin accounts. Profit after tax (PAT) for the quarter was ₹52 crores, up 72% year-on-year, with a PAT margin of 2.7%. Profit attributable to owners was ₹38 crores, up 37% year-on-year.
Net working capital days improved to 61 days from 66 days a year ago. Return on Capital Employed (ROCE) doubled year-on-year to 21.1%, and Return on Equity (ROE) moved from 9% to 20.4%. The MedTech segment is expected to be a key driver for medium-term margin improvement, with revenue projected to cross ₹1,000 crores organically in FY27. Operationally, the company serves over 72,000 retail customers and 2,300 hospital customers, supported by 138 warehouses across 19 states.
The company reaffirmed its FY27 guidance of approximately 23% consolidated revenue growth (excluding new acquisitions), an EBITDA margin of 5%, and EBITDA to operating cash flow conversion of 50%. Management expressed confidence in Entero becoming India's leading integrated healthcare product distribution company over the next decade.
What to do with a filing like this
Entero Healthcare Solutions Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Entero Healthcare Solutions Limited. Read the original for the full detail.